Physician profile
Alan S Friedman
NPI 1598867285
$4,252.53
in general payments reported to CMS, 2019-2025
30 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $341 · 2021: $648 · 2022: $305 · 2023: $710 · 2024: $662 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Education: $21.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.22 |
| Education | $21.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.26 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $608.00 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $440.43 | 2019-2025 | Tavneos, Parsabiv |
| Akebia Therapeutics INC | $351.50 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $275.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.43 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $180.33 | 2019-2025 | Jardiance, Mounjaro |
| Horizon Therapeutics Plc | $129.36 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $124.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $88.50 | 2019 | |
| Novo Nordisk INC | $87.55 | 2022-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $84.43 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $83.99 | 2019-2024 | Velphoro |
| Scpharmaceuticals INC. | $82.15 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $78.23 | 2021-2023 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $71.39 | 2024 | |
| Ani Pharmaceuticals, INC. | $67.99 | 2024-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $67.35 | 2024 | Ibsrela |
| Pfizer INC. | $59.14 | 2019 | |
| Shield Therapeutics INC | $45.50 | 2023 | Accrufer |
| Glaxosmithkline, LLC. | $44.44 | 2019-2023 | Benlysta |
| Alnylam Pharmaceuticals INC. | $38.65 | 2023-2024 | Givlaari |
| Exact Sciences Corporation | $32.71 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $31.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.85 | 2024 | |
| Kyowa Kirin, INC. | $27.47 | 2023 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.21 | 2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $21.03 | 2023 | Rayaldee |
| Mallinckrodt Enterprises LLC | $17.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.